Immutep Operational Update - MarketWatch marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Efti clinical trial status updates
Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022
Sydney, AUSTRALIA, Dec. 15, 2020 (GLOBE NEWSWIRE) Immutep (Formerly known as Prima Biomed) Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs.
Eftilagimod alpha (“efti”) Update
AIPAC - Phase IIb clinical trial
The Company presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, first Overall Survival (OS) data and is on track to report final overall survival data and overall response rate by mid calendar year 2021. Currently there are more than 66% of events compared to approx. 60% which were the basis of the OS data presented at the San Antonio Breast Cancer Conference.
How I m Playing Astra-Zeneca on Vaccine and Acquisition News thestreet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestreet.com Daily Mail and Mail on Sunday newspapers.
Here’s a deeper look.
NIO Stock Has a Technical Floor at $40
It appears that NIO stock has established a strong technical floor around $40.
NIO stock briefly dropped below $40 in early December, before quickly recovering back above $40. The same thing happened again two weeks later. NIO stock dropped below $40. But only a for moment. Then quickly recovered to $40-plus prices.
In other words, recent trading action on NIO stock shows that there is ample demand to buy NIO stock below $40. I don’t expect that demand to waver anytime soon.
It also helps that NIO stock is offering 68 million American Depository Shares at $39 per share. That pricing further cements $40 at a floor for NIO stock. As does the fact that NIO stock’s 50-day moving average sits at $38.
NIO Stock Tumbles after the Company Announces Share Sale
Last Updated: December 11, 2020
NIO stock was trading sharply lower in early trading today after the company announced an ADS (American Depository Shares) issue, its third for the year. Over the last week, other electric vehicle producers have also announced share issuance.
While NIO stock has come off its recent highs, it is still up over 1,000% for the year. That’s nothing short of a turnaround for the Chinese electric vehicle maker that had raised concerns over its ability to continue as a “going concern” as early as March 2020.
NIO won the survival battle